Epidemiology and survival analyses of 333 adult glioma patients from Eastern Algeria (2008-2016)

Abstract

Background: Gliomas are a relatively rare group of tumors with a poor prognosis. We aimed to describe and analyze the clinical characteristics and survival of patients with glioma tumors of Eastern Algeria.
 Methods: A retrospective study was conducted at the University Hospital of Constantine. Medical records of patients enrolled between January 2008 and October 2016 were consulted. Demographic characteristics, clinical data, treatment strategy and dates of last follow-up or death were collected. Chi-square test was used for checking associations, Kaplan- Meier methodology for estimating the survival, and the cox model for identifying prognosis factors.
 Results: A total of 333 patients composed our cohort. The mean age was 48.07 years, and men were 1.87 times more frequent than women. High grade tumors were mainly observed among adults and old adults and in supra-tentorial locations. More than half of the patients had a large resection and a curative protocol of oncological treatment (50.7% and 57%, re- spectively). The mean overall survival was 45.4 months, the median was 21.7 months, and survival rates at 1-, 2-, and 5-years were: 62.8%, 48.5% and 32.9% respectively. Age, histology, grade of malignancy and oncological treatment were the major prognosis factors.
 Conclusion: Our sample was relatively young with a higher survival compared to others.
 Keywords: Glioma; epidemiology; Algeria.

Nuclear Factor-Kappa B in Gliomas as a Predictive Factor for Tumor Recurrence – A Clinicopathological Study

“…Another study conducted by Touati et al, included 333 patients, the mean age was 48.07 years, and men were 1.87 times more frequent than women. This is also close to surveillance, epidemiology, and end result program, where 44.8% of glioma cases were reported in middle-aged patient group (40-62 years) and maleto-female ratios of approximately 1.3:1 was observed in all histology subgroups [7], [8], [9].…”

“…Forty-three patients (39.1%) had Grade IV gliomas. Highest frequency of Grade IV gliomas is compatible with studies of Rasmussen et al, 2017) who examined 1930 patients registered in the danish neuro-oncology registry from 2009 to 2014, and included 1364 (71%) Grade IV Glioblastoma cases, meanwhile Grade II and Grade III cases presented in the same study were 247 (12.8%) and 279 (14.5%) cases, respectively, with 40 (2.1%) Grade I cases, as well as the studies of Touati et al, who examined the 333 biopsies of gliomas and included 183 (55%) Grade IV cases, meanwhile Grade II and Grade III cases presented in the same study were 65 (19.5%) and 72 (21.6%) cases, respectively, with 13 (4%) Grade I cases [8], [10].…”

Twenty years of African Health Sciences as infections continue to plague our continent

“…This section is diverse but with very interesting papers. Hence we have a paper on the “Epidemiology and survival analyses of 333 adult glioma patients from Eastern Algeria 28 ; “Prostate hyperplasia in St Mary's Hospital Lacor: utility of prostate specific antigen in screening for prostate malignancy 29 ; and “Frequency of IL-10+CD19+ B cells in patients with prostate cancer compared to patients with benign prostatic hyperplasia;” 30 and one on breast cancer and the p53 gene. 31 …”

Effect of miR‑29a‑3p in exosomes on glioma cells by regulating the PI3K/AKT/HIF‑1α pathway

“…Glioma is the commonest primary malignancy of the central nervous system. Despite the current combination of surgical and pharmacological treatment options for glioma, the global incidence of glioma remains high and most patients are already at a very malignant stage at the time of presentation, with a 5-year survival rate of <10% and some patients have a survival period of <2 years ( 1 ) therefore, it is crucial to explore the pathological mechanisms of glioma to find more effective treatments for the disease.…”